Literature DB >> 19016744

Cancer stem cells and chemoradiation resistance.

Hideshi Ishii1, Masaaki Iwatsuki, Keisuke Ieta, Daisuke Ohta, Naotsugu Haraguchi, Koshi Mimori, Masaki Mori.   

Abstract

Cancer is a disease of genetic and epigenetic alterations, which are emphasized as the central mechanisms of tumor progression in the multistepwise model. Discovery of rare subpopulations of cancer stem cells (CSCs) has created a new focus in cancer research. The heterogeneity of tumors can be explained with the help of CSCs supported by antiapoptotic signaling. CSCs mimic normal adult stem cells by demonstrating resistance to toxic injuries and chemoradiation therapy. Moreover, they might be responsible for tumor relapse following apparent beneficial treatments. Compared with hematopoietic malignancies, conventional therapy regimes in solid tumors have improved the overall survival marginally, illustrating the profound impact of treatment resistance. This implies that the present therapies, which follow total elimination of rapidly dividing and differentiated tumor cells, need to be modified to target CSCs that repopulate the tumor. In this review article, we report on recent findings regarding the involvement of CSCs in chemoradiation resistance and provide new insights into their therapeutic implications in cancer.

Entities:  

Mesh:

Year:  2008        PMID: 19016744     DOI: 10.1111/j.1349-7006.2008.00914.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  53 in total

Review 1.  Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches.

Authors:  Cristóbal Aguilar-Gallardo; Emily Cecilia Rutledge; Ana M Martínez-Arroyo; Juan José Hidalgo; Santiago Domingo; Carlos Simón
Journal:  Stem Cell Rev Rep       Date:  2012-09       Impact factor: 5.739

2.  CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell line HCT-116.

Authors:  Claudia Dittfeld; Antje Dietrich; Susann Peickert; Sandra Hering; Michael Baumann; Marian Grade; Thomas Ried; Leoni A Kunz-Schughart
Journal:  Radiother Oncol       Date:  2010-03       Impact factor: 6.280

3.  Cancer stem cell-related factors are associated with the efficacy of pre-operative chemoradiotherapy for locally advanced rectal cancer.

Authors:  Kazuaki Hiroishi; Masafumi Inomata; Kenji Kashima; Kazuhiro Yasuda; Norio Shiraishi; Shigeo Yokoyama; Seigo Kitano
Journal:  Exp Ther Med       Date:  2011-03-21       Impact factor: 2.447

4.  Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells.

Authors:  Jun Sunayama; Atsushi Sato; Ken-ichiro Matsuda; Ken Tachibana; Kaori Suzuki; Yoshitaka Narita; Soichiro Shibui; Kaori Sakurada; Takamasa Kayama; Arata Tomiyama; Chifumi Kitanaka
Journal:  Neuro Oncol       Date:  2010-09-22       Impact factor: 12.300

Review 5.  Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies.

Authors:  Shinji Tanaka; Shigeki Arii
Journal:  J Gastroenterol       Date:  2011-02-25       Impact factor: 7.527

6.  Ablation of breast cancer stem cells with radiation.

Authors:  Steven P Zielske; Aaron C Spalding; Max S Wicha; Theodore S Lawrence
Journal:  Transl Oncol       Date:  2011-08-01       Impact factor: 4.243

Review 7.  Cancer stem cells and cancer therapy.

Authors:  Sara Soltanian; Maryam M Matin
Journal:  Tumour Biol       Date:  2011-02-12

Review 8.  Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy.

Authors:  Yingmei Wang; Ping Ji; Jinsong Liu; Russell R Broaddus; Fengxia Xue; Wei Zhang
Journal:  Mol Cancer       Date:  2009-02-13       Impact factor: 27.401

9.  Pancreatic cancer spheres are more than just aggregates of stem marker-positive cells.

Authors:  Margherita Gaviraghi; Patrizia Tunici; Silvia Valensin; Marco Rossi; Cinzia Giordano; Letizia Magnoni; Mario Dandrea; Licia Montagna; Rossana Ritelli; Aldo Scarpa; Annette Bakker
Journal:  Biosci Rep       Date:  2011-02       Impact factor: 3.840

10.  Genotoxic therapy stimulates error-prone DNA repair in dormant hepatocellular cancer stem cells.

Authors:  Shimpei Nishikawa; Hideshi Ishii; Naotsugu Haraguchi; Yoshihiro Kano; Takahito Fukusumi; Katsuya Ohta; Miyuki Ozaki; Daisuke Sakai; Taroh Satoh; Hiroaki Nagano; Yuichiro Doki; Masaki Mori
Journal:  Exp Ther Med       Date:  2012-03-22       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.